Table 2 Association between CIN-1-month and overall survival in patients with metastatic colorectal cancer receiving TAS-102

Overall

0.22 (0.12–0.38)

< 0.0001

Strata

 Men

0.15 (0.06–0.33)

< 0.0001

 Women

0.31 (0.13–0.67)

0.0023

 Rectal

0.36 (0.15–0.78)

0.0092

 Colon

0.15 (0.06–0.34)

< 0.0001

 RAS-mutant

0.32 (0.15–0.64)

0.001

 RAS-wild type

0.14 (0.05–0.35)

< 0.0001

 Older adults (age > 65 years)

0.19 (0.09–0.40)

< 0.0001

 Younger adults (age ≤ 65 years)

0.21 (0.07–0.52)

0.0003

 Higher Baseline CEA (> 55 ng/ml)

0.26 (0.11–0.56)

0.0004

 Lower Baseline CEA (≤ 55 ng/ml)

0.18 (0.07–0.42)

< 0.0001

 Higher Baseline Neutrophil Count (> 4300/mm³)

0.25 (0.08–0.57)

0.0005

 Lower Baseline Neutrophil Count (≤ 4300/mm³)

0.27 (0.11–0.65)

0.0035

Absolute Neutrophil cutoff at 1-month

 CIN-1-month (< 1000/mm³)

0.34 (0.16–0.66)

0.0008

 CIN-1-month (< 1500/mm³)

0.22 (0.12–0.38)

< 0.0001

 CIN-1-month (< 2000/mm³)

0.28 (0.17–0.47)

< 0.0001

 CIN-1-month (< 2500/mm³)

0.25 (0.16–0.42)

< 0.0001

 CIN-1-month (< 3000/mm³)

0.26 (0.16–0.43)

< 0.0001